ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. UroGen Pharma's annualizedNet Income for the quarter that ended in Mar. 2026 was €-81.6 Mil.
UroGen Pharma's average Total Assets over the quarter that ended in Mar. 2026 was €195.3 Mil. Therefore, UroGen Pharma's annualized ROA % for the quarter that ended in Mar. 2026 was -41.76%.
The historical rank and industry rank for UroGen Pharma's ROA % or its related term are showing as below:
FRA:UR8'
s ROA % Range Over the Past 10 Years
Min: -91.68 Med: -66.94 Max: -9.15
Current: -60.8
During the past 11 years, UroGen Pharma's highest ROA % was -9.15%. The lowest was -91.68%. And the median was -66.94%.
FRA:UR8's ROA % is ranked worse than 69.84% of 1419
companies
in the Biotechnology industry
Industry Median: -32.84
vs FRA:UR8: -60.80
UroGen Pharma (FRA:UR8) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
UroGen Pharma ROA % Related Terms
UroGen Pharma ROA % Historical Data
* Premium members only.
The historical data trend for UroGen Pharma's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, UroGen Pharma's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's ROA % distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
UroGen Pharma (FRA:UR8) has a ROA % of -41.76% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on UroGen Pharma and its competitors. According to the industry distribution chart, UroGen Pharma ranks #991 out of 1419 companies in the Biotechnology industry, placing it in the top 69.8%.
Is UroGen Pharma's ROA % too high?
UroGen Pharma's current ROA % is -41.76%. Based on the distribution chart, UroGen Pharma ranks #991 out of 1419 companies in the Biotechnology industry, which is below the industry midpoint. Overall, UroGen Pharma has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's ROA % compare to SEPN and FTRE?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #991 out of 1419 companies for ROA %. This places UroGen Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on UroGen Pharma and its competitors. UroGen Pharma's current ROA % is -41.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €16.47, compared to a current price of €29.77 — trading 80.8% above its estimated fair value. The current ROA % is -41.76%. UroGen Pharma's overall GF Score™ is 61/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current ROA % is -41.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (FRA:UR8) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of €29.77 is trading 80.8% above its estimated GF Value™ of €16.47.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for FRA:UR8:
ROA %: -41.76%
GF Value™: €16.47 vs. price of €29.77 (80.8% above fair value)
No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
61GF Score
Get the complete analysis for FRA:UR8
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UR8 has been successfully added to your 
